Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results.
Injection of botulinum toxin (BT) and pneumatic dilatation are available methods in nonsurgical treatment of achalasia. Authors anticipate beneficial effect of prior BT injection on the success of pneumatic dilatation and duration of its effect. There are no long-term data available to assess efficacy of combined treatment. From 1998 to 2007, 51 consecutive patients (20 men and 31 women, age 24-83) with achalasia were included and prospectively followed up. Each patient received injection of 200 IU of BT into the lower esophageal sphincter (LES) during endoscopy and 8 days later pneumatic dilatation (PD) under X-ray control was performed. The follow-up was established every 3 months first year and then annually. The efficacy was evaluated by a questionnaire concerning patient's symptoms and manometry. Results were compared with 40 historical controls (16 men and 24 women, age 26-80) treated by PD alone using the same method and follow-up. Fifty-one patients underwent combined treatment. Four patients failed in follow-up and were not included for analysis. The mean duration of follow-up was 48 months with range 12-96 months. Thirty-four of forty-seven (72%) patients were satisfied with results with none or very rare and mild troubles at the time of the last visit. Forty-one patients were followed up more than 2 years. Effect of therapy lasted in 75% (31/41) of them. In 17 patients, more than 5 years after treatment, effect lasted in 12 (70%). Mean tonus of LES before therapy was 29 mm Hg (10-80), 3 months after therapy decreased to 14 mmHg (5-26). The cumulative 5 years remission rate (+/-95% CI) in combined treated patients 69% +/- 8% was higher than in controls 50% +/- 9%; however it, was not statistically significant (P= 0.07). In control group 1, case of perforation (2.5%) occurred. Eight patients (17%) with relapse of dysphagia were referred to laparoscopic Heller myotomy with no surgical complication. The main adverse effect was heartburn that appeared in 17 patients (36%). Initial injection of BT followed by PD seems to be effective for long-term results with fewer complications. But the combined therapy is not significantly superior to PD alone.
Kroupa
R
R
Department of Internal Medicine and Hepatogastroenterology, University Hospital and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. rkroupa@fnbrno.cz
Hep
A
A
Dolina
J
J
Valek
V
V
Matyasova
Z
Z
Prokesova
J
J
Mrazova
J
J
Sedmik
J
J
Novotny
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002404:Catheterization / Q000379:methods*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003680:Deglutition Disorders / Q000209:etiology / Q000601:surgery; D004931:Esophageal Achalasia / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D004939:Esophageal Perforation / Q000209:etiology; D049630:Esophageal Sphincter, Lower / Q000187:drug effects / Q000503:physiopathology; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006356:Heartburn / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D010535:Laparoscopy; D008137:Longitudinal Studies; D008297:Male; D008365:Manometry; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D009853:Omeprazole / Q000627:therapeutic use; D017060:Patient Satisfaction; D011446:Prospective Studies; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D016896:Treatment Outcome; D055815:Young Adult
D009465:Neuromuscular Agents; D054328:Proton Pump Inhibitors; D019274:Botulinum Toxins, Type A; D009853:Omeprazole